Refractory Ewing Sarcoma Clinical Trial
Official title:
Phase II Trial of Linsitinib (Anti-IGF-1R/IR) in Patients With Relapsed and/or Refractory Ewing Sarcoma
This is an international, multi-centre, single arm Bayesian designed phase 2 study to identify and determine the safety and activity of anti-IGF-1/IR inhibition in patients with relapsed and/or refractory ESFT. Approximately 40 patients will be recruited from 5-7 European centres. Each patient will be treated with single agent linsitinib, 600 mg orally once a day for days 1-3, 8-10 and 15-17 on a 21 day cycle until disease progression or undue toxicity.
An important development in ES has been the identification of IGF-1R pathway dependency. The
reasons for the remarkable single agent efficacy observed in a small subset of patients
remains unknown, as is the relative lack of efficacy in the majority of patients. There may
be heterogeneity in response due to partial signal pathway inhibition at the tumour level,
inherent resistance in ES cells or the presence of alternative pathway activation through
IR-A receptor signalling.
Here we aim to establish pharmacodynamic responses in ES tumours using functional imaging
18FDG-PET-CT and repeat post treatment biopsy for biomarker responses, toxicity and clinical
outcome to the dual anti-IGF-1R/IR kinase blocking single agent linsitinib.
This is a single arm phase 2 study utilising adaptive Bayesian analysis. Approximately 40
patients will be recruited the national bone sarcoma centre in 5 EU countries over 18 months.
Eligible patients will take 4x 150 mg tablets once a day, days 1-3 of the week followed by 4
days off - repeated for 3 weeks = one treatment cycle. Patients can remain on treatment for
as long as they gain clinical benefit.
The primary objectives are to determine the effect of linsitinib on the patient's tumours in
terms of changes in biomarker and PET scans and to establish the safety of the trial drug
(linsitinib) in Ewing sarcoma at the dose and treatment schedule being used in the trial.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04284774 -
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
|
Phase 2 | |
Recruiting |
NCT04851119 -
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03698994 -
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Active, not recruiting |
NCT04320888 -
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
|
Phase 2 | |
Recruiting |
NCT05734066 -
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02867592 -
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04901702 -
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03155620 -
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
|
Phase 2 | |
Active, not recruiting |
NCT04195555 -
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Completed |
NCT04661852 -
Cabozantinib With Topotecan-Cyclophosphamide
|
Phase 1 | |
Active, not recruiting |
NCT05071209 -
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03526250 -
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
|
Phase 2 |